An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

Inclusion Criteria:

• Have completed the final active treatment in study JADV (NCT01710358), JADZ (NCT01711359), JADX (NCT01721057), JADW (NCT01721044), JADA (NCT01185353) or JAGS (NCT02265705)

Exclusion Criteria:

• Have significant uncontrolled cerebro-cardiovascular (eg, myocardial infarction [MI],unstable angina, unstable arterial hypertension, severe heart failure, orcerebrovascular accident), respiratory, hepatic, renal, gastrointestinal, endocrine,hematologic, neuropsychiatric disorders, or abnormal laboratory values that developedduring a previous baricitinib study that, in the opinion of the investigator, pose anunacceptable risk to the participant if investigational product continues to beadministered
• Have a known hypersensitivity to baricitinib or any component of this investigationalproduct
• Had investigational product permanently discontinued at any time during a previousbaricitinib study
• Had temporary investigational product interruption at the final study visit of aprevious baricitinib study and, in the opinion of the investigator, this poses anunacceptable risk for participation in the study
• Have any other condition that, in the opinion of the investigator, renders theparticipant unable to understand the nature, scope, and possible consequences of thestudy or precludes the participant from following and completing the protocol